A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
NCT07304089
Central Nervous System Diseases, Dyskinesias
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT07111663
This is an observational study in individuals with isolated (or primary) dystonia that involves more than one body region. The purpose of the study is to collect detailed information to help your physician and other researchers understand how dystonia impacts your and other patients' lives and how the disease changes over time. The study may also help researchers better understand the clinical scales that are commonly used to evaluate dystonia symptoms and how they affect various areas of life such as well-being, pain, relationships and social interactions, and progress over time. Because this is an observational study, you will not receive any interventional treatment in the study.
Interested in participating?
Request Info12 year–65 year
All sexes
Observational
Vima Site #004, Scottsdale, Arizona, United States
The primary goal of this observational study is to further characterize and quantify disease severity and impact (including change over time) in individuals with either segmental, multifocal, or generalized dystonia in a structured manner, utilizing and comparing various well-known scales. In addition, medication history and any intercurrent events related to the participant's health (such as, but not limited to, hospitalizations, new diagnoses, etc.) will be captured. This study will provide standardized data to support planned future interventional clinical studies in this patient population and will provide a greater understanding of the population under study and the performance of clinical ratings scales.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Each participant must meet the following criteria at Visit 1 to be eligible to continue in the study:
Exclusion criteria
Any participant who meets any of the following criteria at Visit 1 will be excluded from this study:
Time frame: From start of treatment through 4 months
The BFM was developed to quantitatively assess primary dystonias (Burke 1985). It is composed of 2 subscales: a movement subscale, based on the clinician's evaluation of the patient in nine body areas, and a disability subscale, based on the participant's report of disability in activities of daily living.
Time frame: From start of treatment through 4 months
The TWSTRS-2 scale is used to assess cervical dystonia. It includes 3 subscales that evaluate symptom severity, disability, and pain. The severity scale is clinician-rated and the disability scale is patient-rated based on 6 items related to work, activities of daily living, driving, reading, watching TV, and outside activities.
Time frame: From start of treatment through 4 months
The CGI-S score is used by the Investigator to determine, in a global sense, how severe the patients' blepharospasm is in the context of other blepharospasm patients. Increased scores indicate more severe symptoms.
Contact information is provided by the study sponsor or research team.
Vima Therapeutics
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07304089
Central Nervous System Diseases, Dyskinesias
Birmingham, Alabama, United States
View Trial DetailsNCT02689466
Central Nervous System Diseases, Cervical Dystonia
Bethesda, Maryland, United States
View Trial DetailsNCT02504905
Central Nervous System Diseases, Cervical Dystonia
Bethesda, Maryland, United States
View Trial DetailsNCT01168388
Blepharospasm, Central Nervous System Diseases
Hangzhou, Zhejiang, China
View Trial Details